EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adding Intranasal to Oral Administration of an Ultra-Rapid Near-Universal Drug Regimen Accelerates Relapse-Free Cure of Tuberculosis in Mice

Bai-Yu Lee iD, Daniel L Clemens iD, Saša Masleša-Galic, Susana Nava, Chiao-Yueh Lo iD, Jeffrey I Zink iD, Marcus A Horwitz iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Bai-Yu Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense CDMRP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously identified a potent 4-drug oral regimen comprising clofazimine, bedaquiline, pyrazinamide, and delamanid (parabolic response surface [PRS] regimen V) that dramatically shortens by approximately 85% the treatment duration needed to attain relapse-free cure of tuberculosis in mice compared with the standard regimen. Here, we investigated if intranasal administration of the PRS regimen V antibiotics bedaquiline and delamanid on top of the oral regimen would further accelerate tuberculosis cure in mice. We show that adding the intranasal to oral regimen further lowers lung burden of tubercle bacilli and significantly more rapidly achieves relapse-free cure. Hence, adding inhalational to oral therapy can potentially accelerate cure of tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsTuberculosisAnimalsAdministration, IntranasalAdministration, OralMiceOxazolesDiarylquinolinesNitroimidazolesFemalePyrazinamideClofazimineMycobacterium tuberculosisLungDisease Models, AnimalDrug Therapy, Combination

Stichwörter der Autor:innen

bedaquilinedelamanidintranasal therapyrelapse-free curetuberculosis

Substanzen

Antitubercular AgentsOxazolesbedaquilineDiarylquinolinesNitroimidazolesOPC-67683PyrazinamideClofazimine

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California, USA.
  • California NanoSystems Institute, University of California, Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Bai-Yu Lee, Daniel L Clemens, Chiao-Yueh Lo, Jeffrey I Zink, Marcus A Horwitz

Förderung

  • Department of Defense CDMRP

Zitieren

APA

Lee, B. Y., Clemens, D. L., Masleša-Galic, S., Nava, S., Lo, C. Y., Zink, J. I., & Horwitz, M. A. (2025). Adding Intranasal to Oral Administration of an Ultra-Rapid Near-Universal Drug Regimen Accelerates Relapse-Free Cure of Tuberculosis in Mice. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf315

Vancouver

Lee BY, Clemens DL, Masleša-Galic S, Nava S, Lo CY, Zink JI, et al. Adding Intranasal to Oral Administration of an Ultra-Rapid Near-Universal Drug Regimen Accelerates Relapse-Free Cure of Tuberculosis in Mice. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf315

BibTeX
@article{Lee2025,
  author = {Lee, Bai-Yu and Clemens, Daniel L and Masleša-Galic, Saša and Nava, Susana and Lo, Chiao-Yueh and Zink, Jeffrey I and Horwitz, Marcus A},
  title = {Adding Intranasal to Oral Administration of an Ultra-Rapid Near-Universal Drug Regimen Accelerates Relapse-Free Cure of Tuberculosis in Mice},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf315}
}
Kostenlos starten →